SOURCE: Equity Markets, Inc.

June 17, 2011 09:00 ET

Research Report on Biodel Inc. and Halozyme Therapeutics, Inc. -- Revolutions in Health Care Boost Industry

MACAU--(Marketwire - Jun 17, 2011) - Today, www.EquityMarketsInc.com announced its research report highlighting Biodel Inc. (NASDAQ: BIOD) and Halozyme Therapeutics, Inc. (NASDAQ: HALO). Full content and research is available at www.EquityMarketsInc.com/research.php.

This sector demonstrates renewed investor interest as new and lucrative therapies come to market. The FDA approved the first new drug in 50 years to treat the auto-immune disorder lupus in March 2011, and we expect approval of new treatments for Hepatitis C virus around mid-year. The 2010 health care reform act authorized by the FDA, will establish a regulatory pathway for approving "biosimilar" drugs, which in turn will increase production and shorten FDA approval times. Longer term, it is expected that a wider acceptance of biomarker research and genetic-targeted clinical studies to help limit expense. It is viewed that therapeutics for cancer and infectious diseases and autoimmune and inflammatory treatments are primary growth areas.

Equity Markets has reviewed Biodel Inc. as a development-stage biopharmaceutical company focused on the development and commercialization of treatments for diabetes. It develops its product candidates by applying its formulation technologies to existing drugs. Its product candidate is Linjeta. It has formulated Linjeta as rapid-acting mealtime insulin for the treatment of patients with Type I and Type II diabetes. The full research report on Biodel Inc. (NASDAQ: BIOD) is available here: www.EquityMarketsInc.com/researchfile4634.php.

Equity Markets is covering Halozyme Therapeutics, Inc. as a biopharmaceutical company engaged in the development and commercialization of products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The Company's products are based on property covering the family of human enzymes known as hyaluronidases. "Halozyme's Enhanze technology is the perfect fit for our recombinant human alpha 1-antitrypsin program," stated Randal J. Kirk, CEO and chairman of the board of Intrexon and board member of Halozyme. The full research report on Halozyme Therapeutics, Inc. (NASDAQ: HALO) is available here: www.EquityMarketsInc.com/researchfile4891.php.

About Equity Markets
Our mission at Equity Markets is to be the best source of content and research, while educating, enlightening and informing investors. Equity Markets combines street smart analysts and professional market researchers to provide investors with detailed company profiles and market coverage.

Contact Information